Adjuvant; Consensus; Endometrial neoplasms; Practice guideline; Surgery; Treatment; Body Mass Index; Endometrial Neoplasms/diagnosis; Endometrial Neoplasms/therapy; Female; Follow-Up Studies; Humans; Italy; Medical Oncology/methods; Practice Guidelines as Topic; Medical Oncology; Hematology; Oncology; Radiology, Nuclear Medicine and Imaging
Abstract :
[en] The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11-13 December 2014 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of endometrial cancer. Before the conference, the expert panel prepared three clinically-relevant questions about endometrial cancer relating to the following four areas: Prevention and screening, surgery, adjuvant treatment and advanced and recurrent disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. Results of this consensus conference, together with a summary of evidence supporting each recommendation, are detailed in this article. All participants have approved this final article.
Disciplines :
Oncology
Author, co-author :
Colombo, Nicoletta; Division of Medical Gynecologic Oncology, European Institute of Oncology and University of Milan-Bicocca, Milan, Italy. Electronic address: clinicalguidelines@esmo.org
Creutzberg, Carien; Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands
Amant, Frederic; Department of Gynecological Oncology, University Hospital Leuven, Leuven, Belgium, Center for Gynecological Oncology Amsterdam (CGOA), Antoni van Leeuwenhoek, Amsterdam, The Netherlands
Bosse, Tjalling; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
González-Martín, Antonio; Medical Oncology Department, GEICO, Madrid, Spain, MD Anderson Cancer Center, Madrid, Spain
Ledermann, Jonathan; Department of Oncology and Cancer Trials, UCL Cancer Institute, London, United Kingdom
Marth, Christian; Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
Nout, Remi; Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands
Querleu, Denis; Department of Surgery, Institut Bergonié, Bordeaux, France, Gynecology and Obstetrics Department, McGill University Health Centre, Montreal, Canada
Mirza, Mansoor Raza; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Sessa, Cristiana; Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group
Goffin, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique (CHR) ; As member of ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group
Angela Corstorphine of Kstorfin Medical Communications Ltd provided medical writing support with the preparation of this manuscript. This support was funded by ESMO.
[1] WHO. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012; http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (3 April 2015, date last accessed).
[2] Lee, N.K., Cheung, M.K., Shin, J.Y., et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol 109 (2007), 655–662.
[3] National Cancer Institute. Endometrial cancer treatment Physician Data Query (PDQ). 2015; http://www.cancer.gov/cancertopics/pdq/treatment/endometrial/healthprofessional (1 April 2015, date last accessed).
[4] ACOG, ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 106 (2005), 413–425.
[5] Kandoth, C., Schultz, N., Cherniack, A.D., et al. Integrated genomic characterization of endometrial carcinoma. Nature 497 (2013), 67–73.
[6] Reid-Nicholson, M., Iyengar, P., Hummer, A.J., et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 19 (2006), 1091–1100.
[7] Broaddus, R.R., Lynch, H.T., Chen, L.M., et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 106 (2006), 87–94.
[8] Colombo, N., Preti, E., Landoni, F., Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 (2013), vi33–vi38.
[9] Dykewicz, C.A., Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 33 (2001), 139–144.
[10] World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Report. Food, Nutrition, Physical Activity, and the Prevention of Endometrial Cancer. 2013; http://www.dietandcancerreport.org (2 April 2015, date last accessed).
[11] Garg, K., Soslow, R.A., Endometrial carcinoma in women aged 40 years and younger. Arch Pathol Lab Med 138 (2014), 335–342.
[12] Esposito, K., Chiodini, P., Capuano, A., et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 45 (2014), 28–36.
[13] Zhang, Y., Liu, H., Yang, S., et al. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers 29 (2014), e21–e29.
[14] Rosato, V., Zucchetto, A., Bosetti, C., et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol 22 (2011), 884–889.
[15] Luo, J., Beresford, S., Chen, C., et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer 111 (2014), 1432–1439.
[16] Barry, J.A., Azizia, M.M., Hardiman, P.J., Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20 (2014), 748–758.
[17] Fader, A.N., Arriba, L.N., Frasure, H.E., von Gruenigen, V.E., Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 114 (2009), 121–127.
[18] Ali, A.T., Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer 24 (2014), 384–393.
[19] Peiretti, M., Colombo, N., Sex cord-stromal tumors of the ovary. Textbook of Gynaecological Oncology, 2012, Günes Publishing, Ankara and Istanbul pp. 453-456.
[20] Brinton, L.A., Berman, M.L., Mortel, R., et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 167 (1992), 1317–1325.
[21] Zucchetto, A., Serraino, D., Polesel, J., et al. Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev 18 (2009), 316–321.
[22] Fisher, B., Costantino, J.P., Wickerham, D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998), 1371–1388.
[23] Lancaster, J.M., Powell, C.B., Chen, L.M., Richardson, D.L., Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 136 (2015), 3–7.
[24] Smith, R.A., Cokkinides, V., Brawley, O.W., Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 59 (2009), 27–41.
[25] Jacobs, I., Gentry-Maharaj, A., Burnell, M., et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 12 (2011), 38–48.
[26] National Cancer Institute. Endometrial Cancer Screening Physician Data Query (PDQ). 2015; www.cancer.gov/cancertopics/pdq/screening/endometrial/HealthProfessional/ (2 April 2015, date last accessed).
[28] Fu, Y., Zhuang, Z., Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. Int J Clin Exp Pathol 7 (2014), 6419–6429.
[29] Manchanda, R., Saridogan, E., Abdelraheim, A., et al. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Arch Gynecol Obstet 286 (2012), 1555–1562.
[30] Vasen, H.F., Blanco, I., Aktan-Collan, K., et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62 (2013), 812–823.
[31] Duska, L.R., Garrett, A., Rueda, B.R., et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol 83 (2001), 388–393.
[32] Evans-Metcalf, E.R., Brooks, S.E., Reale, F.R., Baker, S.P., Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 91 (1998), 349–354.
[33] Rodolakis, A., Biliatis, I., Morice, P., et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: clinical recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients. Int J Gynecol Cancer 25 (2015), 1258–1265.
[34] Leitao, M.M. Jr., Kehoe, S., Barakat, R.R., et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 113 (2009), 105–108.
[35] Ushijima, K., Yahata, H., Yoshikawa, H., et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25 (2007), 2798–2803.
[36] Kinkel, K., Kaji, Y., Yu, K.K., et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 212 (1999), 711–718.
[37] Minig, L., Franchi, D., Boveri, S., et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 22 (2011), 643–649.
[38] Kim, M.K., Seong, S.J., Song, T., et al. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Gynecol Oncol 130 (2013), 470–473.
[39] Gallos, I.D., Yap, J., Rajkhowa, M., Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 207 (2012), 266.e1–266.e12.
[40] Park, J.Y., Kim, D.Y., Kim, J.H., et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer 49 (2013), 868–874.
[42] Erkanli, S., Ayhan, A., Fertility-sparing therapy in young women with endometrial cancer: 2010 update. Int J Gynecol Cancer 20 (2010), 1170–1187.
[43] Yamazawa, K., Hirai, M., Fujito, A., et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 22 (2007), 1953–1958.
[44] Koskas, M., Uzan, J., Luton, D., et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 101 (2014), 785–794.
[45] Mittal, K., Soslow, R., McCluggage, W.G., Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med 132 (2008), 402–423.
[46] Sun, H., Enomoto, T., Fujita, M., et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol 115 (2001), 32–38.
[47] Orbo, A., Nilsen, M.N., Arnes, M.S., et al. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol 22 (2003), 141–148.
[48] Hecht, J.L., Pinkus, J.L., Pinkus, G.S., Enhanced detection of atypical hyperplasia in endometrial polyps by PTEN expression. Appl Immunohistochem Mol Morphol 12 (2004), 36–39.
[49] Monte, N.M., Webster, K.A., Neuberg, D., et al. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res 70 (2010), 6225–6232.
[50] Allison, K.H., Upson, K., Reed, S.D., et al. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia. Int J Gynecol Pathol 31 (2012), 151–159.
[51] Quick, C.M., Laury, A.R., Monte, N.M., Mutter, G.L., Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia. Am J Clin Pathol 138 (2012), 678–684.
[52] Tashiro, H., Isacson, C., Levine, R., et al. P53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150 (1997), 177–185.
[53] Zheng, W., Khurana, R., Farahmand, S., et al. P53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol 22 (1998), 1463–1473.
[54] Jia, L., Liu, Y., Yi, X., et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 14 (2008), 2263–2269.
[55] Lax, S.F., Kendall, B., Tashiro, H., et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88 (2000), 814–824.
[56] Castrillon, D.H., Lee, K.R., Nucci, M.R., Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 21 (2002), 4–10.
[57] Saad, R.S., Mashhour, M., Noftech-Mozes, S., et al. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin. Int J Gynecol Pathol 31 (2012), 57–65.
[58] Netzer, I.M., Kerner, H., Litwin, L., et al. Diagnostic implications of p16 expression in serous papillary endometrial cancer. Int J Gynecol Cancer 21 (2011), 1441–1445.
[59] Bagby, C., Ronnett, B.M., Yemelyanova, A., et al. Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin. Int J Gynecol Pathol 32 (2013), 433–443.
[60] Hashi, A., Yuminamochi, T., Murata, S., et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 22 (2003), 374–377.
[61] Köbel, M., Kalloger, S.E., Carrick, J., et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 33 (2009), 14–21.
[62] Al-Hussaini, M., Stockman, A., Foster, H., McCluggage, W.G., WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44 (2004), 109–115.
[63] Egan, J.A., Ionescu, M.C., Eapen, E., et al. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 23 (2004), 119–122.
[64] Eriksson, L.S., Lindqvist, P.G., Flöter Rådestad, A., et al. Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists. Ultrasound Obstet Gynecol 45 (2015), 476–482.
[65] Epstein, E., Blomqvist, L., Imaging in endometrial cancer. Best Pract Res Clin Obstet Gynaecol 28 (2014), 721–739.
[66] Scholten, A.N., Smit, V.T., Beerman, H., et al. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 100 (2004), 764–772.
[67] Helpman, L., Kupets, R., Covens, A., et al. Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. Br J Cancer 110 (2014), 609–615.
[68] Stephan, J.M., Hansen, J., Samuelson, M., et al. Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecol Oncol 133 (2014), 499–505.
[69] Antonsen, S.L., Høgdall, E., Christensen, I.J., et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand 92 (2013), 1313–1322.
[70] Yildiz, A., Yetimalar, H., Kasap, B., et al. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 164 (2012), 191–195.
[71] Mutz-Dehbalaie, I., Egle, D., Fessler, S., et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol 126 (2012), 186–191.
[72] Sun, C., Chen, G., Yang, Z., et al. Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis. Fertil Steril 100 (2013), 782–787.
[73] Walker, J.L., Piedmonte, M.R., Spirtos, N.M., et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 27 (2009), 5331–5336.
[74] Mourits, M.J., Bijen, C.B., Arts, H.J., et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol 11 (2010), 763–771.
[75] Zullo, F., Falbo, A., Palomba, S., Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 207 (2012), 94–100.
[76] Pakish, J., Soliman, P.T., Frumovitz, M., et al. A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecol Oncol 132 (2014), 366–371.
[77] Tozzi, R., Malur, S., Koehler, C., Schneider, A., Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy?. Gynecol Oncol 97 (2005), 4–9.
[78] Siesto, G., Uccella, S., Ghezzi, F., et al. Surgical and survival outcomes in older women with endometrial cancer treated by laparoscopy. Menopause 17 (2010), 539–544.
[79] Palomba, S., Falbo, A., Mocciaro, R., et al. Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs). Gynecol Oncol 112 (2009), 415–421.
[80] Palomba, S., Falbo, A., Russo, T., Zullo, F., Updating of a recent meta-analysis of randomized controlled trials to assess the safety and the efficacy of the laparoscopic surgery for treating early stage endometrial cancer. Gynecol Oncol 114 (2009), 135–136.
[81] Walker, J.L., Piedmonte, M.R., Spirtos, N.M., et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30 (2012), 695–700.
[82] Fader, A.N., Seamon, L.G., Escobar, P.F., et al. Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers. Gynecol Oncol 126 (2012), 180–185.
[83] Han, K.H., Park, N.H., Kim, H.S., et al. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer. Gynecol Oncol 134 (2014), 293–296.
[84] Garg, G., Gao, F., Wright, J.D., et al. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol 128 (2013), 77–82.
[85] Lutman, C.V., Havrilesky, L.J., Cragun, J.M., et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 102 (2006), 92–97.
[86] Abu-Rustum, N.R., Iasonos, A., Zhou, Q., Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?. Am J Obstet Gynecol 198 (2008), 457.e1–457.e5 discussion 457.e5–457.e6.
[87] Cragun, J.M., Havrilesky, L.J., Calingaert, B., et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23 (2005), 3668–3675.
[88] Kilgore, L.C., Partridge, E.E., Alvarez, R.D., et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56 (1995), 29–33.
[89] Creasman, W.T., Morrow, C.P., Bundy, B.N., et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer 60 (1987), 2035–2041.
[90] Abu-Rustum, N.R., Gomez, J.D., Alektiar, K.M., et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol 115 (2009), 236–238.
[91] Dowdy, S.C., Aletti, G., Cliby, W.A., et al. Extra-peritoneal laparoscopic para-aortic lymphadenectomy–a prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol 111 (2008), 418–424.
[92] Mariani, A., Dowdy, S.C., Cliby, W.A., et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109 (2008), 11–18.
[93] Ballester, M., Dubernard, G., Lécuru, F., et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 12 (2011), 469–476.
[94] Abu-Rustum, N.R., Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging. J Natl Compr Canc Netw 12 (2014), 288–297.
[95] Benedetti Panici, P., Basile, S., Maneschi, F., Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100 (2008), 1707–1716.
[96] Kitchener, H., Swart, A.M., Qian, Q., et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373 (2009), 125–136.
[97] Naumann, R.W., The role of lymphadenectomy in endometrial cancer: was the ASTEC trial doomed by design and are we destined to repeat that mistake?. Gynecol Oncol 126 (2012), 5–11.
[98] Smith, D.C., Macdonald, O.K., Lee, C.M., Gaffney, D.K., Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer 18 (2008), 255–261.
[99] Trimble, E.L., Kosary, C., Park, R.C., Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 71 (1998), 340–343.
[100] Todo, Y., Kato, H., Kaneuchi, M., et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 375 (2010), 1165–1172.
[101] Chan, J.K., Cheung, M.K., Huh, W.K., et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 107 (2006), 1823–1830.
[102] Kim, H.S., Suh, D.H., Kim, M.K., et al. Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis. Jpn J Clin Oncol 42 (2012), 405–412.
[103] Vargas, R., Rauh-Hain, J.A., Clemmer, J., et al. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol 133 (2014), 216–220.
[104] Takano, M., Ochi, H., Takei, Y., et al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?. Br J Cancer 109 (2013), 1760–1765.
[105] Watanabe, Y., Satou, T., Nakai, H., et al. Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol 116 (2010), 1027–1034.
[106] Querleu, D., Morrow, C.P., Classification of radical hysterectomy. Lancet Oncol 9 (2008), 297–303.
[107] Shih, K.K., Yun, E., Gardner, G.J., et al. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol 122 (2011), 608–611.
[108] Vandenput, I., Trovik, J., Vergote, I., et al. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study. Int J Gynecol Cancer 21 (2011), 332–336.
[109] Gokce, Z.K., Turan, T., Karalok, A., et al. Clinical outcomes of uterine carcinosarcoma: results of 94 patients. Int J Gynecol Cancer 25 (2015), 279–287.
[111] Briët, J.M., Hollema, H., Reesink, N., et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol 96 (2005), 799–804.
[112] Cohn, D.E., Horowitz, N.S., Mutch, D.G., et al. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?. Gynecol Oncol 87 (2002), 243–246.
[113] Gadducci, A., Cavazzana, A., Cosio, S., et al. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I–II endometrioid-type endometrial cancer. Anticancer Res 29 (2009), 1715–1720.
[114] Gemer, O., Arie, A.B., Levy, T., et al. Lymphvascular space involvement compromises the survival of patients with stage I endometrial cancer: results of a multicenter study. Eur J Surg Oncol 33 (2007), 644–647.
[115] Guntupalli, S.R., Zighelboim, I., Kizer, N.T., et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol 124 (2012), 31–35.
[116] Blake, P., Swart, A.M., Orton, J., et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373 (2009), 137–146.
[117] Creutzberg, C.L., van Putten, W.L., Koper, P.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 (2000), 1404–1411.
[118] Keys, H.M., Roberts, J.A., Brunetto, V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004), 744–751.
[119] Kong, A., Johnson, N., Kitchener, H.C., Lawrie, T.A., Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 104 (2012), 1625–1634.
[120] Soong, R., Knowles, S., Williams, K.E., et al. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 74 (1996), 562–567.
[121] Salvesen, H.B., Iversen, O.E., Akslen, L.A., Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17 (1999), 1382–1390.
[122] AlHilli, M.M., Mariani, A., Bakkum-Gamez, J.N., et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol 133 (2014), 485–493.
[123] Zeimet, A.G., Reimer, D., Huszar, M., et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 105 (2013), 1142–1150.
[124] Bosse, T., Nout, R.A., Stelloo, E., et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer 50 (2014), 2602–2610.
[125] Sorbe, B., Nordström, B., Mäenpää, J., et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 19 (2009), 873–878.
[126] Nout, R.A., Smit, V.T., Putter, H., et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375 (2010), 816–823.
[127] Sorbe, B., Horvath, G., Andersson, H., et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma–a prospective randomized study. Int J Radiat Oncol Biol Phys 82 (2012), 1249–1255.
[128] Bosse, T., Peters, E.E., Creutzberg, C.L., et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer - A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 51 (2015), 1742–1750.
[129] Bendifallah, S., Canlorbe, G., Raimond, E., et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br J Cancer 110 (2014), 2640–2646.
[130] Creutzberg, C.L., van Putten, W.L., Koper, P.C., et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 89 (2003), 201–209.
[131] McMeekin, D.S., Filiaci, V.L., Aghajanian, C., A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial. Gynecol Oncol, 134, 2014 (abstract LBA 431).
[132] Creasman, W.T., Odicino, F., Maisonneuve, P., et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95 (2006), S105–S143.
[133] Greven, K.M., Randall, M., Fanning, J., et al. Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 19 (1990), 529–534.
[134] Straughn, J.M., Huh, W.K., Orr, J.W. Jr., et al. Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecol Oncol 89 (2003), 295–300.
[135] Creutzberg, C.L., van Putten, W.L., Wárlám-Rodenhuis, C.C., et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22 (2004), 1234–1241.
[136] Sagae, S., Susumu, N., Viswanathan, A.N., et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. Int J Gynecol Cancer 24 (2014), S83–S89.
[137] Morrow, C.P., Bundy, B.N., Homesley, H.D., et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol 36 (1990), 166–171.
[138] Susumu, N., Sagae, S., Udagawa, Y., et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108 (2008), 226–233.
[139] Maggi, R., Lissoni, A., Spina, F., et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95 (2006), 266–271.
[140] Hogberg, T., Signorelli, M., de Oliveira, C.F., et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. Eur J Cancer 46 (2010), 2422–2431.
[141] Greven, K., Winter, K., Underhill, K., et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 103 (2006), 155–159.
[142] Cooke, E.W., Pappas, L., Gaffney, D.K., Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes?. Cancer 117 (2011), 4231–4237.
[143] Page, B.R., Pappas, L., Cooke, E.W., Gaffney, D.K., Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? Revised staging, endometrial cancer, histology. Int J Gynecol Cancer 22 (2012), 593–598.
[144] Pecorelli, S., Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105 (2009), 103–104.
[145] Morrow, C.P., Bundy, B.N., Kurman, R.J., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40 (1991), 55–65.
[146] Wright, J.D., Fiorelli, J., Kansler, A.L., Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. Am J Obstet Gynecol 200 (2009), 419.e1–419.e7.
[147] Klopp, A., Smith, B.D., Alektiar, K., et al. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 4 (2014), 137–144.
[148] Rossi, P.J., Jani, A.B., Horowitz, I.R., Johnstone, P.A., Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis. Int J Radiat Oncol Biol Phys 70 (2008), 134–138.
[149] Randall, M.E., Wilder, J., Greven, K., Raben, M., Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma. Int J Radiat Oncol Biol Phys 19 (1990), 49–54.
[150] Greven, K., Winter, K., Underhill, K., et al. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys 59 (2004), 168–173.
[151] Scotti, V., Borghesi, S., Meattini, I., et al. Postoperative radiotherapy in stage I/II endometrial cancer: retrospective analysis of 883 patients treated at the University of Florence. Int J Gynecol Cancer 20 (2010), 1540–1548.
[152] Jobsen, J.J., Lybeert, M.L., van der Steen-Banasik, E.M., et al. Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma. Int J Gynecol Cancer 18 (2008), 1071–1078.
[153] Crosby, M.A., Tward, J.D., Szabo, A., et al. Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma?. Am J Clin Oncol 33 (2010), 364–369.
[154] Secord, A.A., Geller, M.A., Broadwater, G., et al. A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol 128 (2013), 65–70.
[155] Klopp, A.H., Jhingran, A., Ramondetta, L., et al. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol 115 (2009), 6–11.
[156] Randall, M.E., Filiaci, V.L., Muss, H., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24 (2006), 36–44.
[157] Lee, L.J., Viswanathan, A.N., Combined chemotherapy and radiation improves survival for node-positive endometrial cancer. Gynecol Oncol 127 (2012), 32–37.
[158] Mundt, A.J., McBride, R., Rotmensch, J., et al. Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001), 1145–1153.
[159] Viswanathan, A.N., Macklin, E.A., Berkowitz, R., Matulonis, U., The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol 123 (2011), 542–547.
[160] Hasegawa, K., Nagao, S., Yasuda, M., et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J Gynecol Cancer 24 (2014), S90–S95.
[161] Barney, B.M., Petersen, I.A., Mariani, A., et al. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Radiat Oncol Biol Phys 85 (2013), 109–115.
[162] Berton-Rigaud, D., Devouassoux-Shisheboran, M., Ledermann, J.A., et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. Int J Gynecol Cancer 24 (2014), S55–S60.
[163] Amant, F., The rationale for comprehensive surgical staging in endometrial carcinosarcoma. Gynecol Oncol 99 (2005), 521–522 (author reply 522–523).
[164] Reed, N.S., Mangioni, C., Malmstrom, H., et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44 (2008), 808–818.
[165] Wright, J.D., Seshan, V.E., Shah, M., The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 199 (2008), 536.e1–536.e8.
[166] Clayton Smith, D., Kenneth Macdonald, O., Gaffney, D.K., The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol 88 (2008), 227–232.
[167] Nemani, D., Mitra, N., Guo, M., Lin, L., Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 111 (2008), 82–88.
[168] Wolfson, A.H., Brady, M.F., Rocereto, T., et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107 (2007), 177–185.
[169] Barlin, J.N., Puri, I., Bristow, R.E., Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 118 (2010), 14–18.
[170] Creasman, W.T., Kohler, M.F., Odicino, F., et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 95 (2004), 593–596.
[171] Jhingran, A., Burke, T.W., Eifel, P.J., Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys 56 (2003), 1366–1372.
[172] Vargo, J.A., Kim, H., Houser, C.J., et al. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification. Radiother Oncol 113 (2014), 126–131.
[173] Podzielinski, I., Randall, M.E., Breheny, P.J., et al. Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. Gynecol Oncol 124 (2012), 36–41.
[174] Fishman, D.A., Roberts, K.B., Chambers, J.T., et al. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 61 (1996), 189–196.
[175] Gill, B.S., Kim, H., Houser, C., et al. Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma. Brachytherapy 13 (2014), 542–547.
[176] Thigpen, J.T., Brady, M.F., Alvarez, R.D., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17 (1999), 1736–1744.
[177] Decruze, S.B., Green, J.A., Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 17 (2007), 964–978.
[178] Tangen, I.L., Werner, H.M., Berg, A., et al. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer 50 (2014), 3003–3010.
[179] Lentz, S.S., Brady, M.F., Major, F.J., et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 14 (1996), 357–361.
[180] Thigpen, T., Brady, M.F., Homesley, H.D., et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 19 (2001), 364–367.
[181] Ma, B.B., Oza, A., Eisenhauer, E., et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers–a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14 (2004), 650–658.
[182] Rose, P.G., Brunetto, V.L., VanLe, L., et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78 (2000), 212–216.
[183] Whitney, C.W., Brunetto, V.L., Zaino, R.J., et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004), 4–9.
[184] Fiorica, J.V., Brunetto, V.L., Hanjani, P., et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004), 10–14.
[185] van Wijk, F.H., Aapro, M.S., Bolis, G., et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14 (2003), 441–448.
[186] Thigpen, J.T., Brady, M.F., Homesley, H.D., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22 (2004), 3902–3908.
[187] Fleming, G.F., Brunetto, V.L., Cella, D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22 (2004), 2159–2166.
[188] Miller, D., Filiaci, V., Fleming, G., et al. Late-Breaking Abstract 1: RANDOMIZED phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 125, 2012, 771.
[189] Makker, V., Hensley, M.L., Zhou, Q., et al. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. Int J Gynecol Cancer 23 (2013), 929–934.
[190] Grisham, R.N., Adaniel, C., Hyman, D.M., et al. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience. Int J Gynecol Cancer 22 (2012), 807–811.
[191] Nagao, S., Nishio, S., Michimae, H., et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol 131 (2013), 567–573.
[192] Moore, K.N., Tian, C., McMeekin, D.S., et al. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. Cancer 116 (2010), 5407–5414.
[194] Salvesen, H.B., Carter, S.L., Mannelqvist, M., et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 106 (2009), 4834–4839.
[195] Myers, A.P., New strategies in endometrial cancer: targeting the PI3K/mTOR pathway–the devil is in the details. Clin Cancer Res 19 (2013), 5264–5274.
[196] Yeramian, A., Moreno-Bueno, G., Dolcet, X., et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene 32 (2013), 403–413.
[197] Dutt, A., Salvesen, H.B., Chen, T.H., et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105 (2008), 8713–8717.
[198] Kamat, A.A., Merritt, W.M., Coffey, D., et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13 (2007), 7487–7495.
[199] Salvesen, H.B., Haldorsen, I.S., Trovik, J., Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 13 (2012), e353–e361.
[200] Dedes, K.J., Wetterskog, D., Ashworth, A., et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8 (2011), 261–271.
[201] Aghajanian, C., Sill, M.W., Darcy, K.M., et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 29 (2011), 2259–2265.
[202] Colombo, N., McMeekin, D.S., Schwartz, P.E., et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer 108 (2013), 1021–1026.
[203] Tsoref, D., Welch, S., Lau, S., et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 135 (2014), 184–189.
[204] Aghajanian, C., Filiaci, V.L., Dizon, D.S., A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG86P. J Clin Oncol, 33, 2015 (abstract 5500).
[205] Lorusso, D., Ferrandina, G., Colomb, N., Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III–IV) or recurrent endometrial cancer: the MITO END-2 trial. J Clin Oncol, 33, 2015 abstract 5502.
[206] Werner, H.M., Salvesen, H.B., Current status of molecular biomarkers in endometrial cancer. Curr Oncol Rep, 16, 2014, 403.
[207] Weigelt, B., Banerjee, S., Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol 24 (2012), 554–563.
[208] Konecny, G.E., Finkler, N., Garcia, A.A., Phase 2 study of second-line dovitinib (TKI258) in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or -nonmutated advanced and/or metastatic endometrial cancer. Ann Oncol, 25, 2014, LBA27.
[209] Mackay, H.J., Eisenhauer, E.A., Kamel-Reid, S., et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer 120 (2014), 603–610.
[211] Redig, A.J., Jänne, P.A., Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 33 (2015), 975–977.
